Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant for Weight and Metabolic Risk Factors in Schizophrenia
NCT00547118Phase 2Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rimonabant in obesity, metabolic syndrome, sponsored by University of Maryland, Baltimore. Started Nov 2007; status: terminated.
02
Drugs
rimonabant
03
Conditions
obesitymetabolic syndrome
Beyond the preview
Go deeper on NCT00547118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00547118.